Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors

Genes Chromosomes and Cancer

Volumn 56, Issue 8, 2017, Pages 651-659

  Budczies, Jan ^a,b   Bockmayr, Michael ^a,c   Klauschen, Frederick ^a,b   Endris, Volker ^d   Fröhling, Stefan ^b,d   Schirmacher, Peter ^b,d   Denkert, Carsten ^a,b   Stenzinger, Albrecht ^b,d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR; ANTIGEN PEPTIDE TRANSPORTER 2; B7 ANTIGEN; BETA 2 MICROGLOBULIN; BTLA PROTEIN; CD 276 PROTEIN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR 1; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HHLA 2 PROTEIN; HLA A ANTIGEN; HLA B ANTIGEN; IFNGR 2 PROTEIN; INDUCIBLE T CELL COSTIMULATOR LIGAND; JANUS KINASE 1; JANUS KINASE 2; K RAS PROTEIN; LAG 3 PROTEIN; MESSENGER RNA; PEPTIDES AND PROTEINS; PROGRAMMED DEATH 1 LIGAND 1; PSME 4 PROTEIN; STAT2 PROTEIN; TTP 2 PROTEIN; UNCLASSIFIED DRUG; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1; JAK1 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN;

ACUTE MYELOID LEUKEMIA; ANTIGEN PRESENTATION; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER GENETICS; CANCER IMMUNOLOGY; CLEAR CELL CARCINOMA; COLON ADENOCARCINOMA; CUTANEOUS MELANOMA; CYSTADENOCARCINOMA; CYTOLYSIS; ENDOMETRIUM CARCINOMA; ESOPHAGUS CARCINOMA; GENE DELETION; GENETIC SCREENING; GLIOBLASTOMA; GLIOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INCIDENCE; INTRACELLULAR SIGNALING; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; MALIGNANT NEOPLASM; MICROSATELLITE INSTABILITY; MISSENSE MUTATION; MUTATION RATE; MUTATIONAL LOAD; NONSENSE MUTATION; OVARY ADENOCARCINOMA; PANCREAS ADENOCARCINOMA; PAPILLARY CARCINOMA; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PREVALENCE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; RECTUM CARCINOMA; SARCOMA; SOMATIC MUTATION; SQUAMOUS CELL LUNG CARCINOMA; STOMACH ADENOCARCINOMA; THYROID CARCINOMA; TRANSITIONAL CELL CARCINOMA; UTERINE CERVIX CARCINOMA; UTERUS CARCINOMA; DRUG RESISTANCE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES; SIGNAL TRANSDUCTION;

ANTIGEN PRESENTATION; BETA 2-MICROGLOBULIN; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; JANUS KINASE 1; JANUS KINASE 2; MUTATION RATE; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 85019992730     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22468     Document Type: Article

References (50)

1. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015;348:56–61.
2. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 2015b;161:205–214.
3. Topalian SL, Wolchok JD, Chan TA, et al. Immunotherapy: the path to win the war on cancer? Cell 2015;161:185–186.
4. Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192:5451–5458.
5. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015;348:62–68.
6. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331:1565–1570.
7. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734–1736.
8. Schildberg FA, Klein SR, Freeman GJ, Sharpe AH. Coinhibitory pathways in the B7-CD28 ligand-receptor family. Immunity 2016;44:955–972.
9. Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8:328rv4.
10. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109–1117.
11. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908–918.
12. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167–3175.
13. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454.
14. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909–1920.
15. Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017;389:67–76.
16. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer(OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017;389:255–265.
17. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14:847–856.
18. McLaughlin J, Han G, Schalper KA, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2016;2:46–54.
19. Scheel AH, Dietel M, Heukamp LC, et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol. 2016;29:1165–1172.
20. Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 2015;76–83.
21. Kourie HR, Klastersky J. Immune checkpoint inhibitors side effects and management. Immunotherapy 2016;8:799–807.
22. O'Connor JM, Kircher SM, de Souza JA. Financial toxicity in cancer care. J Commun Support Oncol. 2016;14:101–106.
23. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 2016;16:275–287.
24. Miao D, Van Allen EM. Genomic determinants of cancer immunotherapy. Curr Opin Immunol. 2016;41:32–38.
25. Budczies J, Bockmayr M, Denkert C, et al. Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274): associations with gene expression, mutational load, and survival. Genes Chromosomes Cancer 2016;55:626–639.
26. Gröschel S, Bommer M, Hutter B, et al. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification. Cold Spring Harb Mol Case Stud. 2016;2:a01180.
27. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189–2199.
28. Budczies J, Bockmayr M, Denkert C, et al. Classical pathology and mutational load of breast cancer: integration of two worlds. J Pathol Clin Res. 2015;1:225–238.
29. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124–128.
30. Van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 2015;350:207–211.
31. Chabanon RM, Pedrero M, Lefebvre C, et al. Mutational landscape and sensitivity to immune checkpoint blockers. Clin Cancer Res. 2016;22:4309–4321.
32. Jesinghaus M, Pfarr N, Endris V, et al. Genotyping of colorectal cancer for cancer precision medicine: results from the IPH center for molecular pathology. Genes Chromosomes Cancer 2016;55:505–521.
33. Mehnert JM, Panda A, Zhong H, et al. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Invest. 2016;126:2334–2340.
34. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–2520.
35. Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013;39:11–26.
36. Shin DS, Zaretsky JM, Escuin-Ordinas H, et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 2016;pii:CD-16–1223. [Epub ahead of print]
37. Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375:819–829.
38. Antonia SJ, Vansteenkiste JF, Moon E. Immunotherapy: beyond anti-PD-1 and anti-PD-L1 therapies. Am Soc Clin Oncol Educ Book 2016;35:e450–e458.
39. Ni L, Dong C. New checkpoints in cancer immunotherapy. Immunol Rev. 2017;276:52–65.
40. Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev Immunol. 2013;31:443–473.
41. Thomas SJ, Snowden JA, Zeidler MP, Danson SJ. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer 2015;113:365–371.
42. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015;160:48–61.
43. Akbani R, Akdemir KC, Aksoy BA, et al. Genomic classification of cutaneous melanoma. Cell 2015;161:1681–1696.
44. Bass AJ, Thorsson V, Shmulevich I, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202–209.
45. Johnson BJ, Costelloe EO, Fitzpatrick DR, et al. Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virus-infected mice. Proc Natl Acad Sci USA 2003;100:2657–2662.
46. Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 2016;315:1600–1609.
47. Pitt JM, Vétizou M, Daillère R, et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity 2016;44:1255–1269.
48. Gao J, Shi LZ, Zhao H, et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 2016;167:397–404.
49. Restifo NP, Marincola FM, Kawakami Y, et al. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst. 1996;88:100–108.
50. McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 2017;168:613–628.